Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/17 23:31:36」(JST)

wiki en

Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell.^[1] In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells.

History of available agents

This list is incomplete; you can help by expanding it.

U.S. FDA approval	Name	Description
2002^[2]^[3]	Ibritumomab tiuxetan (Zevalin)	monoclonal antibody anti-CD20 conjugated to a molecule that chelates Yttrium-90.
2003^[4]	Iodine (¹³¹I) tositumomab (Bexxar)	links a molecule containing Iodine-131 to the monoclonal antibody anti-CD20.

These medications were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory non-Hodgkins lymphoma. This means they are used in patients whose lymphoma is refractory to conventional chemotherapy and the monoclonal antibody rituximab. A set of radioimmunotherapy drugs that rely upon an alpha particle-emitting isotope (e.g., Bi-213 or, preferably, Ac-225), rather than a beta emitter, as the killing source of radiation is being developed. The most developed drug is directed to treating acute myeloid leukemia and is in patient clinical trials (as of the fourth quarter of 2010).^{[citation needed]}

Other applications (non-approved indications)

Other types of cancer for which RIT has therapeutic potential include prostate cancer,^[5] metastatic melanoma,^[6] ovarian cancer,^[7] neoplastic meningitis ^[7] , leukemia,^[8] high-grade brain glioma,^[9] and metastatic colorectal cancer.^[10]

References

^ Milenic DE, Brady ED and Brechbiel MW. Antibody-targeted radiation cancer therapy. Nature Rev Drug Discovery 2004; 3:488-98.
^ FIbritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin’s Lymphoma
^ Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin Med Res. 2005 Aug;3(3):157-65.
^ Tositumomab and Iodine I 131 Tositumomab - Product Approval Information - Licensing Action
^ Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304.
^ Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, and Casadevall A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci USA 2004;101: 14865-70.
^ ^a ^b Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96.
^ Burke JM, Jurcic JG. Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185-208.
^ Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):972-5.
^ Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5842-52.

External links

Radioimmunotherapy at the US National Library of Medicine Medical Subject Headings (MeSH)
Radioimmunotherapy.org

This medical treatment–related article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 再発性または難治性の濾胞性リンパ腫の治療 treatment of relapsed or refractory follicular lymphoma
2. 甲状腺髄様癌：化学療法および免疫療法 medullary thyroid cancer chemotherapy and immunotherapy
3. 進行期（III/IV）濾胞性リンパ腫の初期治療 initial treatment of advanced stage iii iv follicular lymphoma
4. 造血細胞移植のための前処置療法 preparative regimens for hematopoietic cell transplantation
5. 濾胞性リンパ腫における自家造血細胞移植 autologous hematopoietic cell transplantation in follicular lymphoma

English Journal

Comparison of (211)At-PRIT and (211)At-RIT of Ovarian Microtumors in a Nude Mouse Model.

Frost SH, Bäck T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, Jensen H, Albertsson P, Lindegren S.Source1 Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg, Sweden .
Cancer biotherapy & radiopharmaceuticals.Cancer Biother Radiopharm.2012 Dec 11. [Epub ahead of print]
Abstract Purpose: Pretargeted radioimmunotherapy (PRIT) against intraperitoneal (i.p.) ovarian microtumors using avidin-conjugated monoclonal antibody MX35 (avidin-MX35) and (211)At-labeled, biotinylated, succinylated poly-l-lysine ((211)At-B-PL(suc)) was compared with conventional radioimmunother
PMID 23230896

Moving Radioimmunotherapy Forward for Follicular Lymphoma.

Witzig TE.SourceMayo Clinic, Rochester, MN.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2012 Dec 10. [Epub ahead of print]
PMID 23233712

Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.

Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.SourceOliver W. Press, Joseph M. Unger, Michael LeBlanc, Ajay K. Gopal, David G. Maloney, Fred Hutchinson Cancer Research Center; Oliver W. Press, Ajay K. Gopal, David G. Maloney, University of Washington Medical Center, Seattle, WA; Lisa M. Rimsza, Catherine Spier, Thomas P. Miller, University of Arizona, Tucson, AZ; Jonathan W. Friedberg, Richard I. Fisher, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY; Myron S. Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Myron S. Czuczman, Bruce D. Cheson, Cancer and Leukemia Group B, University of Chicago, Chicago, IL; Mark Kaminski, University of Michigan, Ann Arbor, MI; Rita M. Braziel, Oregon Health and Science University, Portland, OR; Bruce D. Cheson, Georgetown University Hospital, Washington DC; Shaker R. Dakhil, Wichita Community Clinical Oncology Program, Wichita, KS.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2012 Dec 10. [Epub ahead of print]
PURPOSEAdvanced follicular lymphomas (FL) are considered incurable with conventional chemotherapy and there is no consensus on the best treatment approach. Southwest Oncology Group (SWOG) and Cancer and Leukemia Group B compared the safety and efficacy of two immunochemotherapy regimens for FL in a
PMID 23233710